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NEW FEDERAL STEM CELL 
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MICHAEL ULRICH* 
 
INTRODUCTION 
Billions of dollars have been spent in search of cures for diseases such 
as cancer,1 muscular dystrophy,2 heart disease,3 diabetes,4 Alzheimer’s,5 
and Parkinson’s.6  Medical research has consistently pushed the envelope to 
find new ways to tackle old problems, yet, the field of embryonic stem cell 
research, a field that many believe could be the key to providing new and 
effective treatments, remains relatively underfunded due to concerns over 
ethical considerations.  This is largely because the biggest financial backer 
of scientific research is the federal government,7 and its desire to finance 
 
Copyright © 2011 by Michael Ulrich. 
* J.D. Candidate, 2011, University of Maryland School of Law (Baltimore, Maryland); B.S., 
2004, Biological Resources Engineering, A. James Clark School of Engineering, University of 
Maryland (College Park, Maryland). 
 1. Estimates of Funding for Various Research, Condition, and Disease Categories, NAT’L 
INSTS. OF HEALTH (Feb. 1, 2010), http://report.nih.gov/rcdc/categories/ [hereinafter Estimates of 
Funding]. The National Institutes of Health’s (NIH) financial support for cancer research in 2008 
was $5.57 billion. Id.    
 2. Id. The NIH’s financial support for muscular dystrophy in 2008 was $56 million. Id. See 
also Jerry Lewis’ Telethon Hits Record, USA TODAY, Sept. 3, 2007, available at 
http://www.usatoday.com/life/television/news/2007-09-03-jerry-lewis-telethon_N.htm (stating 
that The Muscular Dystrophy Association Telethon raised $1.46 billion between 1966 and 2007). 
 3. Estimates of Funding, supra note 1. The NIH’s financial support for heart disease 
research in 2008 was $1.217 billion. Id. 
 4. Id. The NIH’s financial support for diabetes research in 2008 was $1.08 billion. Id.   
 5. Id. The NIH’s financial support for Alzheimer’s disease research in 2008 was $412 
million. Id.   
 6. Id. The NIH’s financial support for Parkinson’s disease research in 2008 was $152 
million. Id.   
 7. See James W. Fossett, Beyond the Low-Hanging Fruit: Stem Cell Research Policy in an 
Obama Administration, 9 YALE J. HEALTH POL’Y L. & ETHICS 523, 529 (2009) (finding that 
states have never felt compelled to support research due to funding from the NIH and other federal 
agencies being ubiquitous in biomedical research). 
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embryonic stem cell research has waxed and waned over the years with the 
changing of administrations and the political climate.8  
But on January 23, 2009, the Food and Drug Administration (FDA) 
granted approval to the first clinical trial in the world using human 
embryonic stem cells (hESCs) on people.9  Geron Corporation, a 
biotechnology company in Menlo Park, California, was granted federal 
approval to test the stem cells on eight to ten patients with severe spinal 
cord injuries.10  This authorization to move forward with the trial comes 
just over ten years after the first human embryonic stem cells were isolated, 
at the University of Wisconsin in work financed by Geron,11 and 
approximately ten months after Geron first applied to the FDA to conduct 
the trial.12 
The story of Geron’s efforts to push an embryonic stem cell product to 
market illustrates both the enormous potential and controversy that 
surrounds embryonic stem cell research.  With a goal of ameliorating the 
devastation caused by spinal cord injuries, Geron hopes their embryonic 
stem cells will “help repair the protective myelin sheath around the nerve 
cells, restoring the ability of nerves to carry signals, and perhaps allow 
damaged cells to regenerate.”13  And despite submitting a record 22,500-
page application, the trial was placed in a “clinical hold” by the FDA in 
August 2009.14  It is unclear whether this is due to Congress coaxing the 
FDA in recent years to raise its regulatory hurdles on new products, with 
some of the most stringent being applied to stem cell products,15 or due to 
political considerations from the Bush administration.16  What is clear is 
that less controversial stem cells derived from adults and fetuses have been 
used in clinical trials for years, treating thousands of patients worldwide.17  
 
 8. See infra note 37 and accompanying text (noting that the Obama administration expanded 
the possibilities for stem cell research relative to what was allowed under the George W. Bush 
administration but that the new policies are effectively the same as those under President Clinton).  
 9. Rob Stein, Government Approves Study Using Human Embryonic Stem Cells, WASH. 
POST, Jan. 24, 2009, at A6. 
 10. Id. 
 11. Andrew Pollack, Milestone in Research in Stem Cells, N.Y. TIMES, Jan. 23, 2009, at B1. 
 12. Id. 
 13. Id. 
 14. Scott Gottlieb, Stem Cells and the Truth About Medical Intervention, WALL ST. J., Mar. 
14, 2009, at A9. 
 15. Id. 
 16. Pollack, supra note 11. 
 17. BLOOMBERG NEWS, Study Using Stem Cells is Delayed, N.Y. TIMES, Aug. 19, 2009, at 
B8.  On August 18, 2009, the Geron clinical trial was halted by the FDA after Geron shared data 
from dose escalations studies in animals. Id.  As of February 20, 2010 the Geron clinical trial was 
still on hold. Nicholas Wade, Agency Proposes U.S.-Paid Research on Stem Cells from Early 
Human Egg, N.Y. TIMES, Feb. 20, 2010, at A8. 
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Under President Bush, a moratorium was placed on any research done 
on cell lines that were created after August 9, 2001.18  The Bush 
administration believed that the destruction of human embryos for research 
purposes was not ethically sound enough to warrant governmental support 
through the issuing of federal funds.19  In addition, the Dickey-Wicker 
Amendment prohibits the Department of Health and Human Services 
(HHS), which includes the National Institutes of Health (NIH), from 
funding the creation of embryos for research purposes or from funding 
research where an embryo would be destroyed, discarded, or knowingly 
subjected to risk of injury or death.20  After reviewing the Dickey-Wicker 
Amendment, the Bush administration felt its policy was in line with this 
legislative intent.21  As such, the administration maintained its ethical 
ground that nascent human life should not be destroyed for research 
purposes, while allowing for some good to come of the destruction that had 
already taken place.22 
With limited cell lines approved for federal funds under the Bush 
regime, stem cell research was left largely to the states and the private 
sector as far as funding and determining criteria for what was eligible for 
state funding.23  Although some states chose to prohibit stem cell research, 
or refuse to fund it, a number of states did permit stem cell research,24 
including Maryland.25  These states established their own guidelines and 
review boards to advance the field of stem cell research as they saw fit.26 
Geron’s research was neither affected by the Dickey-Wicker 
Amendment nor by the Bush administration restrictions, because Geron did 
not use federal funds and the embryonic stem cells were derived from one 
 
 18. PRESIDENT’S COUNCIL ON BIOETHICS, MONITORING STEM CELL RESEARCH 189 (2004), 
available at 
http://www.bioethics.gov/reports/stemcell/pcbe_final_version_monitoring_stem_cell_research.pdf 
[hereinafter MONITORING STEM CELL RESEARCH]. 
 19. Id. at 32. 
 20. Balanced Budget Downpayment Act of 1996, Pub. L. No. 104-99, § 128, 110 Stat. 26, 34. 
Embryo includes any organism not protected as a human subject under 45 CFR § 46 “that is 
derived by fertilization, parthenogenesis, cloning, or any other means from one or more human 
gametes.” Id.  
 21. MONITORING STEM CELL RESEARCH, supra note 18, at 32.  
 22. Id. at 34. 
 23. See Fossett, supra note 7, at 532 (finding that state initiatives have established centers for 
policymaking for stem cell research independent of federal influence). 
 24. Stem Cell Research, NAT’L CONF. OF ST. LEGISLATURES (2008),  
http://www.ncsl.org/IssuesResearch/Health/EmbryonicandFetalResearchLaws/tabid/14413/Defaul
t.aspx (identifying California, Connecticut, Illinois, Indiana, Iowa, Maryland, Massachusetts, New 
Jersey, and New York as states that allow some form of stem cell research).   
 25. See MD CODE ANN., ECON. DEV. § 10-429 to 438 (LexisNexis 2008) (setting forth 
Maryland’s rules for stem cell research).  
 26. Fossett, supra note 7, at 532. 
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of the oldest cell lines, which was eligible for federal funding under Bush’s 
policy.27  Yet, the Geron application languished in the FDA before its 
approval in January 2009.28  Geron’s approval coincided with the 
inauguration of President Obama, who had vowed during his campaign to 
remove some of the financing restrictions on embryonic stem cell research 
implemented by the Bush administration.29  Opinions differ on whether the 
timing of the approval was mere coincidence.  Thomas B. Okarma, chief 
executive of Geron, stated that he did not think Bush’s “objections to 
embryonic stem cell research played a role in the FDA’s delaying 
approval,”30 and the FDA insisted that they simply look at the science and 
approve research based on safety.31  Yet, Robert N. Klein, the chairman of 
California’s stem cell research program, felt the approval was directly tied 
to the administration change and even asserted his belief that the Bush 
administration pressured the FDA to delay the trial.32 
Following through on one of his campaign platforms to alter federal 
policy on embryonic stem cell research, on March 9, 2009, President 
Obama issued an Executive Order lifting certain restrictions placed on stem 
cell research by the Bush administration.33  As such, the NIH was given the 
authority to issue new federal guidelines for stem cell research, which went 
into effect on July 7, 2009.34  In light of the newly issued NIH guidelines, 
any state with their own state guidelines for stem cell research must 
determine whether they plan on altering its guidelines to fit within the 
federal scheme.35  While the assumption might be for states to adopt 
requirements set forth by these new guidelines in order to be eligible for 
federal funding, a closer look at the field of stem cell research and its 
history suggests otherwise.36   
 
 27. Stein, supra note 9. 
 28. Pollack, supra note 11. 
 29. Id. 
 30. Id. 
 31. Ron Winslow & Alicia Mundy, Currents – Health: First Embryonic Stem-Cell Trial Gets 
Approved from the FDA, WALL ST. J., Jan. 23, 2009, at A12. 
 32. Pollack, supra note 11. 
 33. Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009).  
 34. NATIONAL INSTITUTE OF HEALTH GUIDELINES ON HUMAN STEM CELL RESEARCH, 74 
FED. REG. 18,578–80 (Apr. 23, 2009) [hereinafter NIH GUIDELINES]; National Institutes of Health 
Guidelines on Human Stem Cell Research, STEM CELL INFORMATION,  
http://stemcells.nih.gov/policy/2009guidelines.htm (last visited Aug. 19, 2011).  
 35. See Varnee Murugana, Embryonic Stem Cell Research: A Decade of Debate from Bush to 
Obama, 82 YALE J. BIOLOGY & MED. 101, 102 (2009) (“The new policy allows federally funded 
researchers to experiment on hundreds of viable ES cell lines restricted under Bush.”). 
 36. See Fossett, supra note 7, at 523 (discussing the expectation of a major shift in stem cell 
research policy with the new administration and the difficulty in assessing the significance of the 
change in federal policy when significant issues were left unresolved).  
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The NIH guidelines expand the possibilities for stem cell research 
relative to those under Bush, yet, they effectively return stem cell research 
to its existence under President Clinton ten years earlier.37  Though more 
cell lines may now be approved or be approvable under the new federal 
guidelines, scientific bodies such as the National Academies (NAS) and 
International Society for Stem Cell Research (ISSCR) have created 
guidelines expanding stem cell research that are accepted and utilized 
internationally.38   
For Maryland, this is a critical juncture in its stem cell history.  It 
recently announced a collaborative partnership in stem cell research with 
California at the 2009 World Stem Cell Summit held in Baltimore, with the 
hopes of generating breakthroughs in the field and obtaining more grant 
money.39  How Maryland responds to the new federal guidelines may 
control how fruitful this collaboration will become.  Seen as a pioneer and 
leader in the field of stem cell research, with a new Center for Stem Cell 
Biology and Regenerative Medicine, Maryland was seen as a likely site for 
the Geron trial.40  If the state intends to maintain this reputation, how it 
moves forward with its stem cell regulations is critical.  In the competition 
for cutting edge research, Maryland must be wary of limiting itself by 
blindly abiding by federal guidelines that may lag behind what is accepted 
in other states, as well as internationally.41 
 
 37. Compare Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009) (allowing funding 
for research on newly created stem cell lines), and NATIONAL BIOETHICS ADVISORY 
COMMISSION, ETHICAL ISSUES IN HUMAN STEM CELL RESEARCH – EXECUTIVE SUMMARY 3 
(1999), available at http://bioethics.georgetown.edu/nbac/execsumm.pdf [hereinafter ETHICAL 
ISSUES] (finding that federal funding could be used to derive cells or cell lines from cadaveric 
fetal tissue or embryos remaining after fertility treatments), with MONITORING STEM CELL 
RESEARCH, supra note 18,  at 189 (stating that federal funds could only be used for research on 
stem cell lines that existed before Aug. 9, 2001). 
 38. THE NATIONAL ACADEMIES’ GUIDELINES FOR HUMAN EMBRYONIC STEM CELL 
RESEARCH (2008 Amendments) [hereinafter NAS GUIDELINES], available at 
http://books.nap.edu/openbook.php?record_id=12260&page=R1; THE INTERNATIONAL SOCIETY 
FOR STEM CELL RESEARCH, GUIDELINES FOR THE CONDUCT OF HUMAN EMBRYONIC STEM CELL 
RESEARCH (2006) [hereinafter ISSCR GUIDELINES], available at 
http://www.isscr.org/guidelines/ISSCRhESCguidelines2006.pdf. 
 39. Danielle Ulman, Maryland Signs Stem Cell Collaboration Deal with California, THE 
DAILY RECORD (Balt.), Sept. 22, 2009. 
 40. Matthew Hay Brown & Stephanie Desmon, Stem Cell Trials Ok’d; Embryonic Tests in 
City Possible, BALTIMORE SUN, Jan. 24, 2009, at A1. 
 41. See Andy Rosen, Is $12.4M in Stem Cell Funding in MD Enough?, THE DAILY RECORD, 
July 27, 2009 (“Comptroller Peter Franchot expressed concern about Maryland’s competitive 
position.”); Fossett, supra note 7, at 532–33 (discussing how most states modeled their guidelines 
on those promulgated by the NAS and ISSCR and the competition between states for researchers 
appears to be increasing). 
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After providing a brief scientific background in Part I,42 ethical issues 
in stem cell research such as embryonic stem cell derivation methods,43 
autonomy and coercion,44 and procedural concerns45 will be examined as 
well.  Part II explores the essential differences between the NIH, NAS, and 
ISSCR guidelines with respect to these ethical considerations and how they 
relate to procurement of materials,46 informed consent,47 and the review 
process.48  Part III discusses Maryland’s current stem cell guidelines,49 
while part IV suggests model guidelines50 that Maryland should utilize.  In 
doing so, Part IV will also examine how Maryland’s guidelines differ, and 
what changes Maryland should make to bring its current guidelines closer 
to the model guidelines.51   
I.  BACKGROUND 
A.  Scientific Background 
Stem cells are important to the field of medical research because they 
are capable of renewing themselves through cell division for long periods of 
time, they are undifferentiated, meaning they have not yet developed into a 
specialized cell type, and they have the potential to become any tissue or 
organ of the researcher’s choosing.52  Scientists primarily work with two 
types of stem cells, embryonic stem cells and adult, or somatic, stem cells.53  
Researchers are also beginning to use induced pluripotent stem cells 
(iPSCs), which are adult stem cells that are genetically reprogrammed to 
become cells that have embryonic stem cell-like properties.54   
Embryonic stem cells are typically derived from spare embryos that 
have been developed through in vitro fertilization (IVF) for reproductive 
purposes and subsequently donated for research purposes when they are no 
 
 42. See infra Part I.A. 
 43. See infra Part I.B.1. 
 44. See infra Part I.B.2. 
 45. See infra Part I.B.3. 
 46. See infra Part II.A. 
 47. See infra Part II.B. 
 48. See infra Part II.C. 
 49. See infra Part III. 
 50. See infra Part IV.A. 
 51. See infra Part IV.B. 
 52. NAT’L INSTS. OF HEALTH, STEM CELL BASICS 3 (2009), available at 
http://stemcells.nih.gov/staticresources/info/basics/SCprimer2009.pdf [hereinafter STEM CELL 
BASICS]. 
 53. Id. at 2. 
 54. Id. at 13. The technical term for these cells with embryonic stem cell-like proprieties are 
human pluripotent stem cells (hPSCs). Id. 
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longer needed for their originally intended use.55  The human embryonic 
stem cells (hESCs) are usually taken when the embryos are four to five days 
old.56  A cell line is then created after the hESCs have replicated in the “cell 
culture for six or more months without differentiating, are pluripotent, and 
appear genetically normal.”57 
The main difference between hESCs and adult stem cells is that hESCs 
can become a cell of any type, while adult stem cells are thought to be 
limited to differentiating to the cell types found in their original tissue.58  In 
addition, growing hESCs in culture is relatively easy, whereas adult stem 
cells are difficult to isolate from an adult tissue and growing them in culture 
is challenging.59  Despite the promise of iPSCs, it is still unknown whether 
there are clinically significant differences between the iPSCs and hESCs.60  
A significant portion of stem cell researchers remain skeptical that iPSCs 
are reliable substitutes for hESCs.61 
B.  Ethical Issues 
While hESCs may have more potential than adult stem cells, because 
of their broader range of differentiation and ease in proliferation, they are 
more controversial.62  The ethical implications of using an embryo to derive 
stem cells are not lost on the nation’s populace, nor are they lost on the 
country’s lawmakers.63  For years the debate over embryos and the 
beginning of human life has tethered stem cell research to contested issues 
such as abortion.  The moral status of embryos and the rights they deserve 
are questions that inevitably arise when dealing with where any hESCs 
come from.  The arguments in this context change depending on the source 
 
 55. Id. at 5. 
 56. Id. The cells are typically taken from a group of cells referred to as the blastocyst. Id. 
 57. Id. 
 58. Id. at 12. 
 59. Id. at 13. 
 60. Id. 
 61. Fossett, supra note 7, at 541. 
 62. See Stephen R. Latham, The Once and Future Debate on Human Embryonic Stem Cell 
Research, 9 YALE J. HEALTH POL’Y L. & ETHICS 483, 486 (2009) (identifying the debate 
surrounding hESCs as concerns about the moral status of the human embryo in vitro against the 
potential of embryonic stem cell and cloning research to deliver lifesaving and life-enhancing 
cures). 
 63. See Robert J. Levine, Federal Funding and the Regulation of Embryonic Stem Cell 
Research: The Pontius Pilate Maneuver, 9 YALE J. HEALTH POL’Y L. & ETHICS 552, 553 (2009) 
(stating that federal officials often try to appeal to both those who believe destruction of embryos 
or creation of human life artificially is wrong and those who believe potential cures for deadly or 
disabling diseases should be pursued to the fullest). 
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of the stem cells.64  While stem cells can be taken from noncontroversial 
sources such as cadaveric fetal tissue or adult stem cells, they also can be 
derived from embryos created by IVF for fertility treatment, embryos 
created by IVF with gametes donated for research, human somatic cell 
nuclear transfer (SCNT), and used for chimera research.65 
 1.  Objections to Stem Cell Derivation Methods 
  a.  Spare Embryos 
Much of the moral objection to embryonic stem cell research resides in 
the status of the embryo itself.  As stated earlier, the destruction of an 
embryo is seen by many to be the killing of a human being, linking the 
argument to those made in discussions on abortion.66  The concept that the 
human embryo is in fact a human being stems mainly from the religious 
perspective that life is created at the time of fertilization.67  The belief that 
human life begins at the moment of fertilization equates the destruction of 
an embryo with the murdering of an adult.68  This religious perspective 
helped shape the United States’ embryonic stem cell policy under President 
Bush.69  Seeing the embryo as a human life, President Bush stated in his 
August 9, 2001 speech on stem cells that “human life is a sacred gift from 
our creator.”70  
Another view is that while an embryo is not a human being, its 
potential for life grants it certain moral status that warrants consideration.71  
This typically means that while embryos do not have to be treated on the 
 
 64. See Latham, supra note 63, at 485 (stating that adult stem cell research has been fairly 
uncontroversial). 
 65. See Stem Cell Basics, supra note 52, at 5, 24 (explaining that embryonic stem cells can be 
derived from embryos created utilizing IVF and somatic cell nuclear transfer); Robert Streiffer, 
Human/Non-Human Chimeras, in THE STANFORD ENCYCLOPEDIA OF PHILOSOPHY § 1 (Edward 
N. Zalta ed., 2010), http://plato.stanford.edu/entries/chimeras/ (discussing how the creation of 
hESCs increased the range of chimera research). 
 66. See Levine, supra note 63, at 563 (discussing how policy makers advocating for 
embryonic stem cell research may be labeled as condoning the murder of innocent babies). 
 67. Pope John Paul II, The Unspeakable Crime of Abortion, in ETHICAL ISSUES IN MODERN 
MEDICINE 545, 546 (Bonnie Steinbock et. al. eds., 7th ed. 2009). 
 68. Id. at 545. 
 69. President George W. Bush, Remarks by President George W. Bush on Stem Cell Research 
(Aug. 9, 2001), in MONITORING STEM CELL RESEARCH, supra note 18, at 183, 186 [hereinafter 
Remarks by Bush]. 
 70. Id. See also Latham, supra note 62, at 486 (quoting White House spokesman Tony Snow 
when asked why President Bush vetoed federal funding for embryonic stem cell research, “The 
simple answer is he thinks murder is wrong.”). 
 71. See Michael J. Sandel, Embryo Ethics – The Moral Logic of Stem-Cell Research, 351 
New Eng. J. Med. 207, 208 (2004) (stating that personhood is not the only warrant for respect and 
that to treat an embryo as a mere thing misses its significance as potential human life). 
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same moral grounds as human beings, their destruction should be for 
purposes that are appropriate for destroying its potential for life.72  Some 
feel that the benefits of embryonic stem cell research are too speculative to 
justify the destruction of this potential, especially considering the fact that 
the prospective benefits could possibly be achieved through less 
controversial forms of stem cell research.73 
However, this argument for special moral status due to the potential 
for life is problematic when facing the argument that any single somatic cell 
or hESC can potentially develop into a human being.74  Moreover, both an 
embryo and somatic cell require external factors to realize their potential.75  
For example, a naturally conceived embryo requires nourishment and 
avoiding dangerous substances while an embryo created through in vitro 
fertilization requires thawing and transferring to a uterus.76  Since it is 
unlikely that anyone would argue for the protection of the trillions of cells 
that contain the potential for life, the argument for special moral status due 
to an embryo’s potential is certainly contested.77 
 b.  Research Embryo 
While the ethical issues mentioned typically deal with embryos created 
for infertility and are no longer needed for that purpose, there are separate 
ethical concerns regarding the creation of embryos for stem cell research.  
Creating embryos through cloning technologies could potentially allow 
researchers to better understand genetic diseases as well as address the issue 
of immune rejection by recipients of stem cell transplants.78  Yet, some feel 
that the creation of embryos specifically for the purpose of destroying them 
for research is not the same as using spare embryos that will most likely be 
discarded.79  Creating an embryo for research or therapies is using them as 
tools from the outset, whereas using embryos that would be discarded is 
salvaging some benefit since the embryo is bound for destruction.80  
Therefore, the creation and utilization of research embryos for stem cell 
research raises its own unique ethical concerns. 
 
 
 72. Id. 
 73. Andrew Siegel, Ethics of Stem Cell Research, in THE STANFORD ENCYCLOPEDIA OF 
PHILOSOPHY §§ 1, 5 (Edward N. Zalta ed., 2008), http://plato.stanford.edu/entries/stem-cells/. 
 74. Id. at 4. 
 75. Id. at 5. 
 76. Id. 
 77. Id. at 4. 
 78. Id. at 8. 
 79. Id. 
 80. Id. 
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 c.  Somatic Cell Nuclear Transfer 
One of the methods for creating these types of research embryos is a 
process known as Somatic Cell Nuclear Transfer (SCNT).81  This is a 
technique that combines an egg whose nucleus has been removed with the 
nucleus of a somatic cell to create an embryo.82  This method of embryo 
creation is controversial because of its capability to be used for reproductive 
cloning.83  This embryo can be grown to produce a full grown organism 
with an identical genetic make-up to the organism that donated the somatic 
cell nucleus.84  For example, this process was used for the first animal 
reproductive cloning to create Dolly the sheep in 1996.85 
While the concept of cloning is highly controversial,86 the SCNT 
process could provide an even greater potential in the field of stem cell 
research in the form of therapeutic cloning.87  Therapeutic cloning uses the 
SCNT process to create an embryo with the same genetics as the somatic 
cell nucleus donor.88  Therefore, scientists can use these embryos to create 
stem cells that can be used to generate tissues that match a patient’s body.89  
This would likely eliminate the serious concern of tissues being created 
from stem cells and then having them rejected by the patient’s immune 
system.90  Yet, some fear that perfecting cloning techniques for therapeutic 
purposes will enable the pursuit of reproductive cloning, and obtaining the 
eggs necessary to create the research embryos could lead to exploitation of 
the women providing those eggs.91 
 d.  Chimeras 
The other ethical stem cell debate revolves around chimeras, which is 
an organism composed of cells with different embryonic origins.92  While 
the fear and controversy over chimeras can bring about thoughts of human-
 
 81. STEM CELL BASICS, supra note 52, at 23–24. 
 82. Id at 23. 
 83. Id. See also, Latham, supra note 62, at 486 (stating that therapeutic cloning is 
controversial because it is uncomfortably close to reproductive cloning). 
 84. STEM CELL BASICS, supra note 52, at 23. 
 85. Id. 
 86. Compare Remarks by Bush, supra note 70, at 185 (“I strongly oppose human cloning, as 
do most Americans.”), with NAS GUIDELINES, supra note 38, § 1.1(a) (covering SCNT, which 
can be used for therapeutic and, theoretically, reproductive cloning), and ISSCR GUIDELINES, 
supra note 38, § 11.1 (allowing for SCNT to be utilized as well).   
 87. STEM CELL BASICS, supra note 52, at 24. 
 88. Id. 
 89. Id. 
 90. Id. 
 91. Siegel, supra note 73, at 8. 
 92. Streiffer, supra note 65, at 2. 
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animal hybrids, the fact is that each person is most likely a chimera given 
the fact that other organisms’ cells become incorporated into our bodies 
through processes that leave the cells intact.93  Other common and naturally 
occurring examples are pregnant women acquiring cells from their fetuses 
or mosquitoes transferring blood between victims.94   
Chimera research is inherently controversial because of the combining 
of human and animal cells, which carries with it the ethical concerns of 
animal research ethics as well as the ethical concerns of embryonic stem 
cell research that were previously discussed.95  Other more unique ethical 
concerns may be present, however, given that the use of chimeras in 
embryonic stem cell research is often met with skepticism and caution, even 
by advisory boards that maintain its general acceptability.96  The ethical 
concerns typically revolve around violating natural species boundaries, 
existence of entities that cannot be definitely classified as either human or 
non-human, fear of great apes that have borderline-personhood, affronts to 
human dignity, and the enhancing of non-human’s moral status.97 
In reality, in terms of embryonic stem cell research, chimera research 
typically refers to the implantation of stem cells into non-human animals 
primarily to do experimental research that cannot ethically be performed on 
humans.98  For example, to determine whether stem cells are pluripotent 
they can be injected into blastocyst-stage embryos, the embryo would be 
brought to term, and then the offspring would be tested for cell potency.99  
Rather than creating a child to ascertain whether hESCs are truly 
pluripotent, they would be injected into postnatal, immune-deficient mice 
and see if they give rise to teratomas.100  Other uses for chimeric research 
include ascertaining whether certain cells could serve as a source for 
possible nervous system repair, determining whether a chick embryo could 
be used as an in vivo system for studying hESC differentiation, and 
clarifying the bases of diseases by examining the behavior of genetically 
diseased lines in live animal models.101   
 
 
 
 93. Id. 
 94. Id. 
 95. Id. at 3. 
 96. Id. 
 97. Id. at 1. 
 98. Id. at 2–3.  
 99. Id. at 3. 
 100. Id. Teratomas are tumors that consist of disorganized tissue growth of the three germ 
layers, endoderm, mesoderm, and ectoderm. Id. 
 101. Id. 
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2.  Autonomy and Coercion 
One of the most important aspects of ensuring ethically sound medical 
research is the process of informed consent.  For consent to be valid, it must 
be informed and voluntary.102  These two guiding principles of informed 
consent help to maintain an individual’s right to autonomy and avoid the 
potential for coercion.103  Problems arise in the field of embryonic stem cell 
research because the research is not being performed on the individual 
giving consent.  This raises questions of when consent should be given, 
who should provide consent, what should the consent cover, and who 
should be requesting the consent.104 
The treatment of infertility is a delicate medical process that many 
suggest should not intermingle with the decision to donate embryos for 
research purposes.105  Donation for research then would only be discussed 
once the infertility treatment is complete and the decision has been made to 
discard the spare embryos.106  The thought is that this will avoid taking 
advantage of people in vulnerable states, and assure that embryos, which 
might otherwise be donated to others for pregnancy, would not be used for 
research.107  A potential problem can arise in cases of “death, divorce, 
separation, failure to pay storage charges, inability to agree on disposition 
in the future, or lack of contact with the program.”108  This is why some 
recommend obtaining written directives at the beginning of the infertility 
treatment regarding disposition of embryos, with donating to research as an 
available option.109 
However, this issue then raises the question of who should provide 
consent, since decisions regarding gametes and embryos can arise 
throughout the infertility treatment process.110  To fully respect the 
autonomy of all donors, embryos should only be used for research if 
consent has been obtained by all parties who have contributed biological 
 
 102. See RUTH R. FADEN & TOM L. BEAUCHAMP, A HISTORY AND THEORY OF INFORMED 
Consent 155 (Oxford U. Press 1986) (stating that consent must be voluntary and informed). 
 103. See id. at 7 (“Respect for autonomy is the most frequently mentioned moral principle in 
the literature on informed consent.”); Christine Grady, Money for Research Participation: Does it 
Jeopardize Informed Consent?, 1 AM. J. OF BIOETHICS 40, 40 (2001) (discussing how coercion is 
a threat to the possibility of voluntary informed consent). 
 104. Bernard Lo et al., Informed Consent in Human Oocyte, Embryo, and Embryonic Stem Cell 
Research, 82 FERTILITY & STERILITY 559, 560 (2004). 
 105. See id. at 562 (stating that certain guidelines find a potential for conflicts of interest if the 
infertility specialist is the same person requesting embryos for research). 
 106. Id. at 561.  
 107. Id. 
 108. Id. 
 109. Id. 
 110. Id. 
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material.111  Alternatively, there are questions about the practicality of 
obtaining consent from all sperm donors given the widespread use of 
anonymous frozen sperm.112  The issue of privacy is also implicated here, 
given that all identifying information may not be removed, linking the 
gamete donor with the embryo used for embryonic stem cell derivation.113 
Generally, it is thought that the consent process should cover “all 
information that a reasonable person would find pertinent to the decision to 
donate their embryo to research.”114  Yet, it is unclear what this entails 
regarding future research that has not been designed or may not even be 
known at the time of consent.115  If general categories are used, rather than 
specific protocols, the question becomes what categories provided would 
give the most informed consent possible.116  On the other hand, if the 
embryo is created for research, rather than created for infertility treatment, 
the consent content must be different.  The consent must be certain to state 
that the embryo created will not be used to cause a pregnancy.117  Again, 
with the importance of privacy, issues surface of how specific can, and 
should, consent be with regards to who will have access to the genetic 
information and how long that linking information will be available.118  An 
added complication becomes the duration of a genetic link, and how this 
applies to the ability of donors to withdraw their consent to research.119 
Finally, the ethical question of who should obtain the consent deals 
with the physician-patient relationship and whether the donor should be 
seen as a research subject or simply a patient.  The physician-patient 
relationship is one of trust where the physician is obligated to advocate for 
the health and well-being of his or her patient.120  To avoid tainting this 
 
 111. Id. at 562. This would include SCNT. Id. at 560. 
 112. Id. at 560. 
 113. Id. The FDA may require linkage to donors in the future when implanting stem cell lines 
in people to document that appropriate testing was carried out for infectious and genetic diseases. 
Id. 
 114. Id. 
 115. See id. at 560–61 (noting that donors can consent to general categories of future research).  
 116. See id. at 561 (stating that more empirical research is needed to determine what categories 
best capture the relevant distinctions among different types of research for donors). 
 117. Id. 
 118. See Jeremy Sugarman, Human Stem Cell Ethics: Beyond the Embryo, 2 CELL STEM CELL 
529, 530–31 (2008) (finding that there is a legitimate concern regarding privacy of information for 
those who provide cells when identifiers are often kept in hopes of using the cells or their 
derivatives in clinical settings). 
 119. See Timothy Caulfield et al., Informed Consent in Embryonic Stem Cell Research: Are we 
Following Basic Principles?, 176 CAN. MED. ASS’N J. 1722, 1723–24 (2007) (discussing the 
fundamental right to withdraw consent and how it applies to embryonic stem cell research). 
 120. See Lois Snyder & Paul S. Mueller, Research in the Physician’s Office: Navigating the 
Ethical Minefield, 38 HASTINGS CENTER REP. 23, 25 (2008) (stating the importance of clinicians 
putting their patients first). 
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relationship, or unjustly using it to coerce a trusting patient into donating 
her embryo for research, some urge that whenever possible, someone other 
than the treating infertility physician should obtain consent to research 
donation.121  This can avoid conflicts of interest and ensure that the 
reproductive needs are the primary focus of the care.122  Additionally, the 
treating physician can ensure that the consent process is actually informed 
and voluntary.123 
If it is possible to have the treating physician and the researcher be 
different individuals, there are compelling reasons to have both parties be 
the one that obtains the consent.  The physician is typically trusted and so 
depended upon that the patient could simply agree to anything the physician 
presents.124  To completely remove the pressure a patient may feel, perhaps 
the physician should not even be aware of what the patient decides.125  
Alternatively, the physician may be more qualified to deal with the stresses 
associated with infertility treatment while discussing the option for research 
donation.126  Being that patients would typically feel more comfortable 
with her physician than an unknown researcher, the patient may actually 
prefer to have the discussion with the physician.127 
3.  Procedural Concerns 
Procedural implementations, such as the review process, are utilized to 
ensure that the ethical concerns raised above are addressed.128  At the 
review process the ethical considerations of stem cell derivation have most 
likely already been decided.  If the stem cells were derived in a manner that 
is legal, the review moves on to the informed consent.129  It is here that the 
committee ensures that the consent to research donation was informed and 
voluntary.130  This is where issues of conflicts of interest, risks and 
 
 121. Lo, supra note 104, at 562. 
 122. Id. 
 123. Id. 
 124. Id. 
 125. Id. 
 126. See id. (“Obstetrician-gynecologists, particularly infertility specialists, are accustomed to 
providing nondirective counseling and respecting a woman’s preferences and values.”). 
 127. See id. (finding that "a patient’s personal physician is considered an impartial source of 
information and advice"). 
 128. See Snyder & Mueller, supra note 120, at 24 (stating that a review board such as an IRB 
should assess all ethical concerns). 
 129. See, e.g., NIH GUIDELINES, supra note 34, § II(A) (stating that once it has been 
determined that the embryos used were created using in vitro fertilization for reproductive 
purposes but were no longer needed the next step is to review the informed consent process).  
 130. Id. at § II(A)(2). 
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benefits, confidentiality, and financial coercion are placed under the 
microscope.131   
The review process can be done by an Internal Review Board 
(IRB),132 a Stem Cell Research Oversight (SCRO) committee,133 or an 
Embryonic Stem Cell Research Oversight (ESCRO) committee.134  The 
IRB’s job is to review a researcher’s proposed study to ensure it complies 
with procedural and ethical requirements, as well as maintaining 
observation of the research during the study to be certain these requirements 
are being followed throughout the study.135  Due to the sensitive and 
controversial nature of embryonic stem cell research, SCRO and ESCRO 
committees were recommended and formed to provide an added layer of 
ethical and scientific review beyond the standard IRB approval.136 
II.  STEM CELL RESEARCH GUIDELINES 
In this section, the stem cell guidelines of the National Institute of 
Health (NIH) will be examined and compared with those provided by both 
the National Academies (NAS) and the International Society for Stem Cell 
Research (ISSCR).  The NIH guidelines were put forth to indicate what 
must be followed for research to be eligible for NIH funds.137  They are not 
binding on those conducting stem cell research without NIH funds.   
The National Academies is a group of organizations that began with 
the National Academy of Sciences that, under the charter granted to it by 
Congress in 1863, has a mandate requiring it to advise the federal 
government on scientific and technical matters.138  As such, the NAS 
guidelines are merely advisory rather than binding.  The NAS Guidelines 
were originally put forth in 2005 by the Committee on Guidelines for 
Human Embryonic Stem Cell Research, but it soon became apparent that 
clarification was needed as well as frequent updating due to the rapid pace 
of developments in stem cell research.139  As a result, the Human 
 
 131. See Snyder & Mueller, supra note 120, at 24 (finding that these types of concerns should 
be addressed by oversight bodies such as an IRB). 
 132. 45 C.F.R. § 46.109 (2009). 
 133. ISSCR GUIDELINES, supra note 38, § 8.1.  
 134. NAS GUIDELINES, supra note 38, § 1.3(a).   
 135. Karen J. Maschke, Human Research Protections: Time for Regulatory Reform?, 38 
HASTINGS CENTER REP. 19, 20 (2008). 
 136. Insoo Hyun, Magic Eggs and the Frontier of Stem Cell Science, 36 HASTINGS CENTER 
REP. 16, 17 (2006). 
 137. NIH GUIDELINES, supra note 34, § I. 
 138. NAS GUIDELINES, supra note 38. Other organizations falling under The National 
Academies include the National Academy of Engineering, The Institute of Medicine, and the 
National Research Council. 
 139. Id. 
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Embryonic Stem Cell Research Advisory Committee was created in 2006 
and amended the guidelines in 2007 and 2008.140   
The ISSCR is an independent, nonprofit organization created in 2002 
to foster the exchange of information on stem cell research.141  The ISSCR 
Task Force formulated its guidelines to articulate the responsibility of 
scientists to ensure human stem cell research is performed according to 
rigorous standards of research ethics and to encourage uniform research 
practices to be followed globally.142  Again, these guidelines, issued in 
2006, are advisory rather than binding. 
A.  Procurement of Materials 
When examining a particular set of guidelines, the first determination 
should be to ascertain the scope of the guidelines by determining the 
derivation methods that are covered.  The NIH guidelines apply to hESCs 
and certain uses of iPSCs,143 defining hESCs as cells that are “derived from 
the inner cell mass of blastocyst stage human embryos, are capable of 
dividing without differentiating for a prolonged period in culture, and are 
known to develop into cells and tissues of the three primary germ 
layers.”144  The NIH guidelines conclude by making it clear that they are 
meant to approve research using hESCs derived from nothing more 
controversial than an IVF embryo created for fertility treatment that is no 
longer needed.145  These guidelines reiterate that NIH funding cannot be 
used for the derivation of stem cells from human embryos due to the 
Dickey-Wicker Amendment.146  Also ineligible for federal funding are 
hESCs derived from sources such as somatic cell nuclear transfer (SCNT), 
parthenogenesis, and IVF embryos created for research purposes.147  
Research involving chimeras is also labeled as ineligible.148 
In contrast, the NAS and ISSCR guidelines cover a much wider variety 
of sources for stem cell research.  The NAS guidelines cover all derivation 
of hESC lines, including those derived from blastocysts made for 
reproduction and made for research and those derived from somatic cell 
 
 140. Id. 
 141. About the ISSCR, INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH, 
http://www.isscr.org/about/index.htm (last visited April 23, 2010).  
 142. ISSCR GUIDELINES, supra note 38, § 2.2–2.3. 
 143. NIH GUIDELINES, supra note 34, § I. 
 144. Id. § II. 
 145. See id. § II(A)(1) (“Research using hESCs derived from other sources, including somatic 
cell nuclear transfer, parthenogenesis, and/or IVF embryos created for research purposes, is not 
eligible for NIH funding.”). 
 146. Id. § V. 
 147. Id. 
 148. Id. § IV. 
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nuclear transfer, parthenogenesis, or androgenesis.149  Similarly, the broad 
scope of the ISSCR guidelines cover cells from gametes, embryos, or 
somatic cells, as well as those from oocytes and embryos generated for 
research purposes, parthenogenesis, androgenesis, nuclear transfer, or other 
means of somatic cell reprogramming.150 
B.  Informed Consent 
Nearly all research regulation is predicated on the necessity of 
participants giving their informed and voluntary consent.  While all of the 
guidelines give specific details about what needs to be included, and there is 
some overlap, the content of those specifications differs.  To be eligible for 
NIH funding, assurance and documentation must be provided to show that: 
all of the options available at that particular infertility facility, including 
donation, were explained; that no payments were offered; the decision 
whether to donate would not affect the quality of care; and there was clear 
separation between the creation and donation of the embryo.151  To ensure 
the last requirement of separation is satisfied, the NIH states that the 
physician responsible for the reproductive clinical care and the researcher 
deriving the hESCs should not be the same person, unless separation was 
not practicable.152  Furthermore, consent for the donation for research 
should have been given at the time of the donation and donors should be 
informed that they retain the right to withdraw their consent to donation up 
until the point where the embryo is actually used or when identifying 
information linking the embryo is no longer retained.153 
The content requirements of the donors’ informed consent is also 
specified in the NIH guidelines.154  The donor must be informed of the 
following: that the embryos would be used to derive hESCs for research; 
what would happen to the embryos in deriving the cells; that the hESCs 
might be kept for many years; that donation was made without restriction or 
direction; that the research was not intended to provide direct medical 
benefit to the donor; that results of the research may have commercial 
potential, but the donor would not receive benefits from that commercial 
potential; and whether information identifying the donor(s) would be 
available to researchers.155 
 
 149. NAS GUIDELINES, supra note 38, § 1.1(a). 
 150. ISSCR GUIDELINES, supra note 38, § 11.1. 
 151. NIH GUIDELINES, supra note 34, § II(A)(3). 
 152. Id. § II(A)(3)(d)(i). 
 153. Id. § II(A)(3)(d)(ii)–(iii). 
 154. Id. § II(A)(3)(e). 
 155. Id.  
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As one would assume from the differentiating scopes, the NAS and 
NIH guidelines differ in many ways.  While there is some overlap with 
certain criteria,156 the NAS requirements are much more extensive and the 
informed consent must be approved by an IRB or foreign equivalent.157  In 
some senses the NAS guidelines may be seen as more permissive.  For 
example, there is no requirement to inform the donor of alternatives to 
donation and it is not explicitly stated that consent must be written.158  On 
the other hand, the NAS guidelines require an explanation that the embryo 
will be destroyed,159 that cells might be genetically manipulated,160 that 
researchers will follow best practices,161 and there must be a statement of 
risks.162  NAS also suggests that in addition to notifying the donors if their 
identities will be ascertainable, the donor must be given the option of being 
re-contacted to receive research results, where lines are traceable.163  
Additionally, the NAS guidelines state that the donor should be given the 
option of consenting to some research and not others to ensure that their 
wishes are honored.164  Under the NAS guidelines, informed consent is 
applicable to all gamete donors, not only those donating the embryo.165 
The ISSCR specifications for the requirements of informed consent are 
understandably extensive, given the amount of research the guidelines 
cover.  With a scope more similar to that found in the NAS guidelines, the 
ISSCR informed consent requirements are largely comparable as well.166  
For example, the ISSCR require explanation that the embryo will be 
 
 156. See NAS Guidelines, supra note 38, § 3.6 (showing that criteria overlapping with the NIH 
guidelines include the following information: that the decision to donate or not will not affect 
future medical care; that the embryos will be used to create research hESCs; that the cells or cell 
lines may be kept for many years; that the donation is made without restriction; that there will be 
no direct medical benefit to the donor, except under autologous donation which is only available 
under the NAS guidelines; and that while commercial benefits may come from the research the 
donor will not be eligible to receive any). 
 157. Id. § 1.3(a). 
 158. See id. § 3.6 (lacking a requirement for informed consent to be written or requiring the 
donor be told of alternatives to donation). 
 159. Id. § 3.6(j). 
 160. Id. § 3.6(a), (g).  Genetic manipulation includes research on human transplantation and 
mixing of human and non-human cells in animal models. 
 161. Id. § 3.6(e). 
 162. Id. § 3.6(l). 
 163. Id. § 3.6(c)–(d). 
 164. Id. § 3.6. 
 165. Id.  
 166. ISSCR GUIDELINES, supra note 38, § 11.3(a) (including similarities that are found in the 
NIH and NAS guidelines, such as: that the decision to donate or not will not affect future medical 
care; that the embryos will be used to create research hESCs; that the cells or cell lines may be 
kept for many years; that the donation is made without restriction; whether identifying information 
will be ascertainable; and that there will be no direct medical benefit to the donor). 
ULRICH.APPENDIX   8:45 PM 
2011] FOLLOW THE LEADER? S-107 
destroyed,167 that the cells derived may be used for research involving 
genetic manipulation,168 and that the donor may limit their donation to 
specific research purposes.169  Moreover, the ISSCR also requires consent 
be obtained from all gamete donors.170   
However, there are other areas where the ISSCR finds itself analogous 
to the NIH guidelines, rather than those of the NAS.  One of the similarities 
between the ISSCR and NIH guidelines is that they both require that 
consent for donation be obtained at the time the materials are donated to the 
research team.171  Yet, the ISSCR allows for a rigorous review by the Stem 
Cell Research Oversight (SCRO) committee, which is an oversight body 
equipped to evaluate the unique aspects of the science,172 to permit the use 
of materials for which prior consent exists but for which re-consent is 
prohibitively difficult.173  Another similarity between the ISSCR and NIH 
guidelines is their desire to keep the researchers from influencing the 
donor’s decision of consent.  The ISSCR states that wherever possible, the 
treating physician should not also be the researcher when related to the 
donation of gametes or the creation of embryos for fertility treatment.174  
The ISSCR also leaves open the possibility that consent may be withdrawn 
at a later date, since donors should be informed that they retain the right to 
withdraw consent until the materials are actually used in research.175  The 
NAS guidelines on the other hand, make no mention of the importance of 
separating the fertility treatment doctor and researcher, whether consent 
must be obtained during donation, or if consent can be withdrawn at a later 
date.176 
There are certain ISSCR consent requirements that address issues 
found in the NIH and NAS guidelines, but slight differences distinguish 
them.  For example, the ISSCR guidelines also require the statement that 
 
 167. Id. § 11.3(a)(ii). 
 168. Id. § 11.3(a)(iv) (including the generation of human-animal chimeras). 
 169. Id. § 11.3(a)(vi) (“[T]he consent shall notify donors, if applicable under governing law, of 
the possibility that permission for broader uses may later be granted and consent waived under 
appropriate circumstances by an ethical or institutional review board.”). 
 170. Id. § 11.2. 
 171. Compare ISSCR GUIDELINES, supra note 38, § 11.2 (requiring consent for donation of 
materials to research be obtained at the time the materials are transferred), with NIH GUIDELINES, 
supra note 34, § II(A)(3)(d)(ii) (stating that consent for donation must be given at the time of 
donation). 
 172. ISSCR GUIDELINES, supra note 38, § 8.1. 
 173. Id. § 11.2. 
 174. Id. § 11.4. 
 175. Id. § 11.2. 
 176. See NAS GUIDELINES, supra note 38, § 3.6 (giving no guidance on who should present 
the informed consent, when it should be presented, and if it may be withdrawn). Other differences 
between the NAS guidelines and the ISSCR and NIH guidelines are the inclusion of the statement 
of risks and a statement that the researchers will use best practices. Id.   
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the derived cell may be kept for many years, but the consent form must 
state that they will be used for future studies which may not be predictable 
at this time.177  The disclosure of potential commercial benefit is required, 
but the ISSCR guidelines require a statement as to whether the donor will or 
will not receive any financial benefits.178  This leaves the door open for 
donors to receive partial commercial benefits gained from research on their 
donation, something clearly prohibited by the NIH and NAS.  Additionally, 
the ISSCR guidelines require the consent document to divulge any present 
or potential future financial benefits to the investigator and the 
institution.179 
The ISSCR guidelines also contain requirements not found in either 
the NIH or NAS guidelines.  All possible alternatives to donating found at 
the infertility facility and elsewhere, must be explained in full.180  For the 
donation of embryos, it is required that it be stated that the embryos will not 
be used to produce a pregnancy.181  And for experiments in embryonic stem 
cell derivation, somatic cell nuclear transfer, somatic cell reprogramming, 
parthenogenesis, or androgenesis, it must be said that the resulting cells 
would carry some or the donor’s entire DNA.182 
C.  The Process of Review 
To be eligible for funding under the NIH guidelines, one must first 
determine if the hESCs were donated in the United States or abroad, and 
whether they were donated on or after the effective date of the guidelines or 
before the guidelines were issued.  For hESCs donated in the United States 
on or after the NIH guidelines’ effective date, the hESCs should have been 
derived from human embryos that: were created using IVF for reproductive 
purposes and no longer needed; were donated by individuals who sought 
reproductive treatment and gave voluntary consent for the embryos to be 
used for research; and for which the consent and documentation can be 
assured.183  These three requirements are often referred to as satisfying 
section “IIA,” which is utilized as a reference point throughout the NIH 
guidelines.184 
For example, hESCs donated in the United States or abroad before the 
effective date must have been derived from human embryos that comply 
 
 177. ISSCR GUIDELINES, supra note 38, § 11.3(a)(iii). 
 178. Id. § 11.3(a)(viii). 
 179. Id. § 11.3(a)(ix). 
 180. Id. § 11.3(a)(xii). 
 181. Id. § 11.3(a)(xiii). 
 182. Id. § 11.3(a)(xiv). 
 183. NIH GUIDELINES, supra note 34, § II(A). 
 184. See, e.g., id. (referring to Section II(A) of the guidelines). 
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with the requirements stated in IIA, or they must be approved by a Working 
Group of the Advisory Committee to the Director (ACD).185  The Working 
Group is comprised of bioethicists, lay persons, and scientists that will 
make recommendations regarding eligibility to the ACD, who will make 
recommendations to the NIH Director, who will ultimately make the final 
decision.186  For hESCs donated outside of the United States on or after the 
effective date, they must have been derived according to IIA as well, or 
there must be assurance that alternative procedures of the foreign country 
were at least as strict as those in IIA.187 
While the previously mentioned Working Group will be reviewing 
numerous applications for federal funding, the more traditional review and 
approval from an IRB is not made a requirement, as it is with most clinical 
research.  The Guidelines state that IRB review may be required under The 
Common Rule,188 if the investigators are engaged in research involving 
human adult stem cells or the stem cells can be linked to living 
individuals.189  This seems peculiar in that local IRBs are typically used in 
situations like this to weed out the research that is clearly ineligible and 
lighten the load for the Working Group.  This type of review can be found 
in both the NAS and ISSCR guidelines.190 
To determine eligibility, the NAS guidelines rely heavily on review 
committees.  Purely in vitro hESCs research using previously derived hESC 
lines must be granted approval by an Embryonic Stem Cell Research 
Oversight (ESCRO) committee.191  An IRB must review the application for 
new procurements of gametes, blastocysts, or somatic cells for the purpose 
of generating new hESC or hPSC lines.192  Unlike the NIH guidelines, the 
NAS allows for hESC and non-hESC research involving nonhuman 
animals, permitted it receives review and approval from an ESCRO 
committee and an Institutional Animal Care and Use Committee 
 
 185. Id. § II(B). 
 186. Id. § II(B)(2). 
 187. Id. § II(C). 
 188. 45 C.F.R. § 46 (2009).  
 189. NIH GUIDELINES, supra note 34, § I. 
 190. See NAS GUIDELINES, supra note 38, § 1.3(a) (stating that an ESCRO committee must 
approve research with in vitro hESCs, which requires an IRB approved informed consent); ISSCR 
GUIDELINES, supra note 38, § 8.2 (discussing that SCRO committee is not meant to replace 
institutional reviews). 
 191. NAS GUIDELINES, supra note 38, § 1.3(a). The ESCRO committee must receive 
documentation of the provenance of the cell lines, including documentation of the use of an 
acceptable informed consent process that was approved by an IRB or foreign equivalent for their 
derivation and documentation of compliance with any additional required review by an IACUC, 
Institutional Biosafety Committee (IBC), or other institutionally mandated review.  Id. 
 192. Id. § 3.1.   
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(IACUC).193  According to the NIH guidelines, research using hESCs or 
iPSCs from eligible sources that are introduced into nonhuman blastocysts 
is prohibited from receiving federal funding.194   
The NAS guidelines also go further in what is allowable research by 
stating that oocytes generated for research through hormonal induction are 
eligible as long as the donor is reimbursed only for direct expenses acquired 
as a result of the procedure.195  This is clearly a distinguishing feature from 
the NIH guidelines which permit no payments of any kind for the donated 
embryos.196 
The ISSCR discusses the importance of creating a Stem Cell Research 
Oversight (SCRO) committee, along the same lines as that discussed in the 
NAS guidelines.197  To be eligible, all experiments using hESC research, 
human embryos, or embryonic cells must have gone through review, 
received approval, and be subject to ongoing monitoring by the SCRO 
committee.198  In addition, the ISSCR says the same process must be done 
for experiments that entail incorporating human totipotent or pluripotent 
cells into animal chimeras.199  The review must include: appropriate 
scientific justification for performing the research using the specified 
material that is required; appropriate expertise and/or training of the 
investigators to perform the stated experiments; and a discussion of 
alternative methods and rationale for employing the requested human 
materials, the proposed methodology, and for performing the experiments 
in a human rather than animal model system.200   
When it comes to IRB review, the ISSCR guidelines make it clear that 
it is necessary due to the fact that derivation of new lines involve the 
procurement of materials from human subjects.201  The SCRO review that 
is recommended by the ISSCR is not to be construed as replacing the 
 
 193. Id. § 7.3(c)(ii). 
 194. NIH GUIDELINES, supra note 34, § IV(A). 
 195. NAS GUIDELINES, supra note 38, § 3.4(b). Permissible reimbursements include costs 
associated with “travel, housing, child care, medical care, health insurance, and actual lost wages. 
No payments beyond reimbursements should be made for donations of sperm for research 
purposes or of somatic cells for use in NT.” Id.   
 196. NIH GUIDELINES, supra note 34, § II(A)(3)(b). 
 197. ISSCR GUIDELINES, supra note 38, § 8.1. 
 198. Id.  
 199. Id. 
 200. Id. § 8.3(i)–(iii). 
 201. Id. § 12.1(a). The review must include: scientific rationale for the need to derive new cell 
lines, justifying the number of embryos needed; researchers must prove appropriate expertise or 
training; there must be a detailed plan for characterization, storage, banking, and distribution of 
new lines; embryos made using nuclear transfer, parthenogensis, androgenesis, or other in vitro 
means cannot be transferred to a human or nonhuman uterus or cultured in vitro intact as embryos 
for longer than fourteen days or until formation of the primitive streak; and there must be a plan to 
safeguard the privacy of the donor information. Id. § 12.1(b)-(f). 
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requirement of IRB approval.202  In fact, the guidelines clarify that there 
may be some research that falls into a category where the experiments are 
permissible after existing and mandated local review, without the SCRO 
process coming into play.203  Yet, most forms of research are included in 
the category of those that are only permissible once there has been SCRO 
review in addition to IRB review.204 
III.  MARYLAND GUIDELINES 
In 2006, Maryland authorized and created state funding for stem cell 
research by passing the Maryland Stem Cell Research Act.205  While the 
Act does not specifically mention human embryonic stem cells, preferring 
the more politically acceptable term “unused material,”206 it also states that 
creation of stem cell lines is not prohibited and it is, therefore, understood 
to approve of the use of hESCs.207  This Act created the Stem Cell 
Research Commission to evaluate and monitor State-wide stem cell 
research, and put the Commission in charge of adopting regulations and 
developing and applying criteria to evaluate grant applications.208  
However, the Commission was not intended to be the only body assessing 
applications, since one of the requirements for eligibility is that an IRB give 
the protocol its stamp of approval.209  In addition to the Commission, the 
Act also created the Maryland Stem Cell Research Fund, whose purpose is 
to promote State-funded stem cell research through the administering of 
grants and loans to those applications that the Commission approves.210 
For researchers to be eligible for State funds, they must meet the 
eligibility requirements that the Act lays out.211  However, the requirements 
 
 202. Id. § 8.2. “Unless the review is specifically designated to be comprehensive, the SCRO 
process shall not replace other mandated reviews such as institutional reviews that assess the 
participation of human subjects in research, or the oversight for animal care, biosafety, or the 
like.” Id.  
 203. Id. § 10.1. 
 204. Id. § 10.2. These types of research include derivation of new human pluripotent cell lines 
by any means; where the identity of the donors are readily discoverable or may become known to 
the investigator; where human totipotent cells or pluripotent stem cells are mixed with pre-
implantation human embryos; where cells of totipotent or pluripotent human origin are 
transplanted into living humans; and research creating chimeric animals using human cells. Id. § 
10.2(a)–(e).   
 205. S. 144, 2006 Leg., 424th Sess. (Md. 2006) (codified at MD CODE ANN., ECON. DEV. § 10-
429 (2006)). 
 206. MD CODE ANN., ECON. DEV. § 10-438 (LexisNexis 2006).  
 207. Id. § 10-430.  
 208. Id. § 10-431 (establishing the Maryland Stem Cell Research Commission); id. § 10-432 
(establishing Maryland Stem Cell Research Commission’s duties). 
 209. Id. § 10-435(a)(1). 
 210. Id. § 10-434. 
 211. Id. § 10-438. 
ULRICH.APPENDIX  
S-112 JOURNAL OF HEALTH CARE LAW & POLICY [VOL. 14:Supp. 
are not nearly as detailed as those established in the federal guidelines.  For 
example, the Act requires that individuals considering donation must be 
provided with sufficient information to allow for an informed and voluntary 
decision.212  The Act goes no further in explaining what is necessary to 
ensure there is informed consent.  Yet, the Act does require that the 
informed consent be written.213  One area where the Act does show 
specificity is in the options that must be conveyed to the individual 
considering donation.  The donor must be presented with the options of 
storing or discarding any unused material, donating any unused material for 
clinical purposes in the treatment of infertility, donating any unused 
material for research purposes, and donating any unused material for 
adoption purposes.214  The Act also restricts some research by prohibiting 
unused material that is donated from being an oocyte.215 
IV.  STATE RESPONSE TO FEDERAL CHANGES 
A.  Model State Guidelines 
The question presented by President Obama’s Executive Order 
broadening the scope of federal funding for hESC research is how states 
should respond.  President Obama’s order certainly is a relief to researchers 
who found the Bush limitations of any indirect contact between federal 
funds and unapproved cell line research cumbersome.216  However, the 
advancement of the field of research as a result of the order may be limited.  
Even President Clinton encouraged researchers to fund the creation of stem 
cell lines from other sources and then apply for federal funds to continue 
the research.217  With a large number of unused embryos currently being 
stored at fertility clinics likely to be destroyed,218 the concern of federal 
funds weighs very little in formulating the model state guidelines described 
in this section.  Instead, the guidelines were determined based on the most 
advanced levels of stem cell research being conducted throughout the 
country and the world. 
 
 
 212. Id. § 10-438(a)(1). 
 213. Id. § 10-438(c). 
 214. Id. § 10-438(a)(2). 
 215. Id. § 10-438(b). 
 216. See Danielle Ulman, Maryland Stem Cell Researcher Pleased that Bush Restrictions are 
Gone, THE DAILY RECORD, Sept. 21, 2009 (quoting Curt Civin, a doctor nationally renowned for 
his research on stem cells as saying the Bush restrictions were “a silly restriction” and “an 
unnatural fence”). 
 217. Fossett, supra note 7, at 527. 
 218. Id. at 528. 
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 1.  Scope of Material Covered 
As seen when comparing the federal guidelines with those of the NAS 
and ISSCR, the material covered is extremely important in determining 
what type of research can be done.219  With the possible ways to create 
stem cells constantly evolving, it is important not to limit what is eligible.  
Furthermore, any state wishing to remain in competition for research would 
be wise not to restrict material qualified for funding beyond what other 
states have made eligible.220 
That said, the material eligible should be as ethically expansive as 
possible.  This does not mean allowing any type of stem cell research to be 
done in the state.  Rather, it suggests the need for a sound review 
process,221 to determine whether certain research proposals are ethically 
sound.  After reviewing the potential material eligible for funding under the 
different guidelines, it seems unreasonable to merely allow research on 
embryos created by IVF for fertility treatment but are no longer needed.  
Significant scientific progress can be made with embryos created for 
research as well as SCNT.222  And while some may consider these methods 
ethically questionable, guidelines used internationally find them morally 
acceptable and scientifically sound.223 
In evaluating its proposals for developing stem cell lines, a state 
should utilize the more expansive scopes as examples and allow for a 
review process to limit research deemed questionable.  The new federal 
guidelines return the state of eligible materials to its place under Clinton; 
yet, even the Clinton guidelines indicated that their recommendations may 
need to be altered in the future.224  With regard to embryos created for 
research, the guidelines stated using this approach was unnecessary at the 
time because cadaveric fetal tissue and embryos remaining after fertility 
treatment provided an adequate supply of research resources.225  Embryos 
made using SCNT was discussed in a similar manner.  It was seen as 
 
 219. See infra Part II.A (comparing the procurement of material allowed by NIH, NAS, and 
ISSCR guidelines). 
 220. Fossett, supra note 7, at 541 (“States see themselves, at least rhetorically, as competing 
with one another for jobs, tax revenue, economic development, and in the case of hESC research, 
research talent and prestige.”). 
 221. See supra I.B.3 (discussing the ethical issues surrounding the review process). 
 222. See supra I.B.1.ii–iii (discussing uses for research embryos and SCNT). 
 223. See NAS GUIDELINES, supra note 38, § 1.1(a) (covering procurement of hESCs from 
blastocysts made specifically for research and using SCNT); ISSCR GUIDELINES, supra note 38, § 
11.1 (allowing for SCNT to be utilized as well). 
 224. See ETHICAL ISSUES, supra note 37, at 5–6 (describing the need to monitor scientific 
progress and utility of techniques such as SCNT to possibly allow funding of this type of research 
in the future). 
 225. Id. at 5. 
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unnecessary to support this type of procedure at the time, but a note was 
made to the significant therapeutic potential and that scientific progress in 
this research should be monitored.226  To avoid being irrelevant in terms of 
the most up to date research being conducted, a state should aim to keep 
with the evolution of the science.  This means the procurement of gametes, 
blastocysts, and somatic cells for generating new cell lines should be 
eligible, including embryos created not only for fertility, but for research 
purposes as well.  Additionally, the SCNT process, as well as 
parthenogenesis and androgenesis should be eligible for funding.  The 
guidelines should also cover any adult stem cells, of which there are 
currently little restrictions, as well as pluripotent stem cells derived in any 
form. 
This type of expansive scope allows and encourages collaboration with 
other states, as well as with potential international partners. With the goal of 
stem cell research being the exploration of all the potential benefits the 
science has to offer, this prospective reward should not be overlooked. 
 2.  Informed Consent 
Informed consent is an extremely important part of the research 
process, ensuring documentation that the donor was completely aware of 
what they were agreeing to.  The informed consent should be written, 
archived, and easily retrievable to provide long-term access to the legal 
source of materials used.  The informed consent is lengthy and detailed, but 
it is imperative that the donor understand exactly what they are participating 
in, or at least their understanding should be assured as much as possible.227   
The informed consent, at a minimum, should contain: all alternatives 
to donation, not simply those alternatives available at that particular 
infertility facility; that the decision to donate or not will not affect future 
care for the patient; that the donation will be used to obtain research hESCs 
and that the embryos will be destroyed in the process; that the stem cells 
will be kept for many years and, as a result, may be used in future research 
that is not yet known; that research may include genetic manipulation, 
including human transplantation or research with chimeras; that no direct 
medical benefit will come to the donor except for autologous donation; 
disclosure of potential commercial benefits for the researcher and that the 
donor will not receive any commercial benefit; a statement of risks; that the 
donation is made without restriction; whether identifying information will 
be available for the researcher; that they retain the right to withdraw consent 
 
 226. Id. at 5–6.  
 227. See, e.g., Moore v. Regents of Univ. of Cal., 793 P.2d 479, 483 (Cal. 1990) (holding that 
the doctor’s failure to disclose commercial benefit received from tissue taken from the patient was 
a breach of fiduciary duty to disclose all pertinent information to provide informed consent). 
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at any time until identifying material is removed or the material is used in 
research; and that researchers will follow best practices.   
This consent should be obtained from all gamete donors, to avoid 
potential problems of conflicting interests.  For example, consent by a 
donor in possession of an embryo may not parallel the interests of the 
gamete donors who created that embryo.  A gamete donor may have been 
willing to consent to the creation of an embryo for fertility treatment, but 
not for the creation of embryos to be used for hESC research.  With 
potentially identifying information in the embryo related to gamete donors, 
it is important that they be informed of the donation process.  When 
possible, the fertility treatment doctor and the researcher should not be the 
same person and the consent should be obtained at the time of donation.  If 
either or both of these are impractical, the review process discussed later 
will determine if the consent is still acceptable. 
 3.  The Process of Review 
The review process on a state level should rely heavily on local review 
boards such as institutional IRBs to provide much of the proposal 
assessment.  Likewise, the ESCRO or SCRO committees already in place at 
various research institutions should be utilized in proposal and research 
evaluations.  As stated in the ISSCR guidelines, the specialized stem cell 
research committees are not meant to replace IRBs or duplicate their efforts, 
rather they should be employed for this medically complicated and 
controversial research to add another layer of protection as well as a 
specialized expertise.228  This reliance affords a state the ability to be more 
expansive in their guidelines with certain criteria.  For example, the 
infertility doctor and the stem cell researcher would ideally be separate.  
However, instead of creating an absolute requirement that they be separate, 
the state can rely on an extensive review process to allow for  situations 
where separation is impossible to still receive funding approval and create 
more research possibilities.  The multilayered review can properly certify 
that there was no reason to exclude the research based on conflict of interest 
or coercion.  
The review processes should examine all relevant steps in the research 
procedure, from obtaining research materials to proposed usage of those 
materials, in determining whether to fund the project.  Furthermore, there 
should be scientific justification for the proposal as well as corresponding 
medical expertise and training appropriate to see it to fruition.  Finally, the 
review should assess any and all financial inducements for the donor.  This 
review should ensure that the donor does not receive any undue financial 
 
 228. ISSCR GUIDELINES, supra note 38, § 8.2. 
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gains from their decision to donate other than reimbursements justified by 
the donation.  These types of reimbursements may include medical 
expenses associated with the donation process, lost wages, travel costs, and 
child care.   
B.  Why Maryland Should Adopt the Model Guidelines 
For Maryland to continue to have a strong presence in the field of stem 
cell research it is vital that it begins to adjust its guidelines to fit with the 
model state guidelines suggested above, rather than those recently issued by 
the NIH.  The field of stem cell research is one that operates on a state level, 
a national level, and a global level.  For Maryland to adopt the guidelines 
set forth by the federal government, they may alienate themselves from the 
state and global research markets.  As shown earlier, the current federal 
guidelines conflict in several areas with internationally accepted regulations 
provided by the NAS and ISSCR, which are guidelines that also mirror 
numerous states within the country.229  Further examination of the order by 
President Obama suggests that progress by the federal government is 
unlikely to be made any time soon.230  While the important factor in 
working within the federal guidelines is being eligible for federal funding, 
this may not be as critical as it would appear.  
Evidence of previous funding for embryonic stem cell research, as 
opposed to stem cell research in general, illustrates that the United States 
government is not even close to providing the type of financial backing that 
would warrant a strict adherence to its guidelines.231  The federal 
government trails state and private donors in support of hESC research,232 
and the odds of a major shift in funding occurring soon are unlikely.233  
NIH funding for stem cell research has increased steadily over the last six 
fiscal years to $938 million, yet, funds dedicated to hESC research 
specifically has increased to approximately nine percent of this, or slightly 
less than $90 million.234  While less controversial stem cell research gets 
 
 229. See Fossett, supra note 7, at 532 (discussing how most states have relied heavily on 
guidelines of the NAS and ISSCR).   
 230. See id. at 537 (stating that the order was narrowly drawn, did not call for an expansion of 
funding for embryonic stem cell research, and as a result there will most likely be only 
incremental change). 
 231. Id. at 528. Spending by NIH for all forms of stem cell research is relatively small and 
hESC support is comparable to that of diagnostic radiology and eye diseases. Id. 
 232. Id. at 536. Since state governments and private foundations are outspending the federal 
government in supporting hESC research they have become major policymakers for stem cell 
research. Id. 
 233. Id. at 524 (noting issues that may preoccupy the government’s attention include the 
national economy, health care, wars in Iraq and Afghanistan, and recent problems in the Middle 
East). 
 234. Id. at 528. 
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the bulk of federal funding,235 advocates of stem cell research have been 
rewarded with their efforts to increase funding in certain states.236 
The largest state supporter of hESC research has been California, 
through the California Institute for Regenerative Medicine (CIRM), which 
has already allocated over $600 million.237  This surpasses the NIH’s 
financial commitment, but so does the 2008 appropriation of $100 million 
by the state of New York.238  While not all states are financing their hESC 
research in the same manner, it is clear from these figures, that research on 
the state level is comparable to, and in some cases exceeds, that on the 
national level.239 
If Maryland hopes to truly harness the potential of the first-ever 
bicoastal agreement they made with California, they should strongly 
consider altering their state guidelines.240  By joining forces with 
California, the largest supporter of hESC research in the world, Maryland is 
giving itself the opportunity to merge into the international alliances that 
have been formed between California and Japan, the United Kingdom, 
Australia, Germany, Canada, and Spain.241  Yet, adhering to federal 
guidelines, rather than adopting the model state guidelines described earlier, 
which are similar to those in California, could hinder the promise this 
opportunity offers.  
The importance of state stem cell guidelines can also be seen in its 
effect on encouraging researchers to carry out their work in particular states 
and the effects this can have on the local economy.242  As a result of its 
active support of stem cell research, Maryland is strongly attractive to top 
 
 235. Id. 
 236. Id. at 529. 
 237. Id. at 530. 
 238. Id. at 531. 
 239. Id.  Differing financial backing comes from annual appropriations, earmarked bonds, 
tobacco settlement revenues, and solicitation of donations. Id. “Ohio and Minnesota have made 
one time appropriations for adult stem cell research and capital construction, respectively.” Id. 
“New Jersey, Illinois, and Connecticut have allocated research grants of varying sizes,” with New 
Jersey approving funds for the construction of a stem cell laboratory.  Id. Connecticut also has 
earmarked $100 million in state funds over the next decade. Id. Massachusetts passed a $1 billion 
life sciences initiative that includes an indeterminate amount for stem cell research, as well as 
providing a proposal for state support of stem cell research that includes $250 million in private 
matching funds to be used in conjunction with state funding. Id. at 531, 535. California solicited 
$18 million in donations from private parties to pay CIRM’s initial operating expenses. Id. at 535. 
 240. See Maryland, California Announce First-Ever Bi-Coastal Agreement to Pool Stem Cell 
Research Grants, TRANSPLANT NEWS, Oct. 1, 2009 (noting the creation of an agreement that will 
allow researchers to form teams and submit joint applications for funding). 
 241. Ulman, supra note 39. 
 242. See Latham, supra note 62, at 488 (stating that by offering their own funds states hope to 
gain a competitive advantage in university and industry development). 
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scientists.243  However, countries such as the Republic of Singapore have 
announced stem cell programs of their own, with the aim of recruiting 
American scientists.244  Even within the United States, where there is still a 
struggling economy, more and more states are realizing the potential boost 
stem cell research can have.245  Michigan, for example, recently ended a 30 
year ban on the destruction of human embryos for stem cell research.246  
One of the main reasons Michigan made this change was that human 
embryonic stem cell scientists prefer working in states that actively support 
their research.247  Similar to Michigan, more states may soon be joining the 
ranks of those who support stem cell research.  This could be problematic 
for Maryland’s hopes of keeping their current scientists given that stem cell 
scientists are sufficiently mobile and “states with permissive research 
policies and appealing recruiting packages should stand a chance of 
successfully attracting researchers.”248  With evidence mounting that state 
stem cell programs are effective tools for state economic development, 
Maryland cannot overlook its financial status when determining how to 
approach its stem cell guidelines.249   
By following ethical standards set forth by expert groups such as the 
NAS and ISSCR, Maryland can maintain its position as a leader in stem cell 
research and provide economic stimulus without sacrificing moral 
principles by adopting guidelines similar to the model ones described 
earlier.  By broadening the scope of its guidelines to cover protocols 
involving SCNT, parthenogenesis, and androgenesis, instead of covering 
merely hESCs and adult stem cells, Maryland can reap the benefits of 
progressive research while the multilayered review process can ensure 
unethical science is not being permitted.  Furthermore, this will allow 
smoother coordination with California who allows these types of 
procedures.250  This would help maximize the potential benefits of the 
 
 243. See Danielle Ulman, World Stem Cell Summit Puts Spotlight on Maryland, THE DAILY 
RECORD, Sept. 18, 2009 (“The states that have invested in this accelerating field of science will 
have a big head start on those that have not.”). 
 244. Fossett, supra note 7, at 542. 
 245. See id. at 541–42 (noting that competition among states and between states and foreign 
countries has encouraged creation of new stem cell initiatives). 
 246. Elisha Baron, Proposal 2: Michigan Voters End 30-Year Ban on the Destruction of 
Human Embryos for Stem Cell Research, 37 J.L. MED. & ETHICS 155, 155 (2009). 
 247. Id. at 157. 
 248. Id. 
 249. See Fossett, supra note 7, at 533 (“[S]tate policies that place few limits on stem cell 
research have been effective in creating awareness among stem cell scientists of differences 
among states, causing permissive states to be seen as more attractive research environments.”). 
 250. The CIRM Medical and Ethical Standards Regulations, CAL. INST. FOR REGENERATIVE 
MED., § 100080 (last updated Aug. 13, 2007), available at 
http://www.cirm.ca.gov/workgroups/pdf/Reformatted_MES_Regs.pdf.  
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collaboration between the two states, rather than having Maryland losing 
researchers to its new partners.251 
Another significant difference between the model guidelines and 
Maryland’s is the requirements to provide informed consent.  Maryland’s 
consent standards are lacking in detail, and should be given greater 
specificity to guide researchers in their consent construction as well as those 
expected to review experimental procedures.  The added detail in the 
consent will also create some restrictiveness to add balance to the expansion 
of allowable materials.  For the scope of the model guidelines may be more 
liberal in what is allowable, but the addition of certain consent criteria, such 
as the statement of risks and explanation of all alternatives to donation, go 
beyond that of the NIH guidelines.  Furthermore, the use of local review 
boards such as IRBs, in addition to the review of the Maryland Stem Cell 
Research Commission, will ensure that funds are provided to research that 
not only follows along with the guidelines provided but is free of conflicts 
of interest and coercion. 
CONCLUSION 
At first glance, adherence to the new federal guidelines would seem 
like common sense.  Yet, analyzing the history of the progress of 
embryonic stem cell research on a federal level, as well as the financial 
support, clearly suggests otherwise.252  In fact, states lead the way in both 
funding and policymaking and this is likely to be the norm for the 
foreseeable future.253  For these reasons, Maryland should be hesitant to 
strictly adopt those guidelines recently set forth by the NIH.  With its recent 
collaborative agreement with California, the largest funder of stem cell 
research in the world, Maryland has the opportunity to join them among the 
leaders in the field of stem cell research.254  To fully realize the potential of 
such a groundbreaking agreement, Maryland should alter its stem cell 
guidelines to fit within the model suggested in this paper, which is largely 
an integration of internationally accepted guidelines put forth by the NAS 
and ISSCR, and very similar to those used in California.   
Establishing new guidelines for eligible material, informed consent, 
and the review process would be a step for Maryland in the direction of 
 
 251. See Fossett, supra note 7, at 542 (noting that CIRM claims at least 45 scientists have 
relocated to CA from other states). 
 252. See id. at 527 (noting the federal policymaking process has not moved hESC research 
policy in any particular substantive direction). 
 253. See id. at 524 (stating that most serious policymaking around stem cell research will 
continue at the state level, rather than through the federal government). 
 254. See supra note 39 and accompanying text (discussing the collaboration deal between 
Maryland and California, which has committed to putting $3 billion toward stem cell research). 
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maximizing the agreement with California as well as creating a path for 
potential future agreements with other states and countries.  The alterations 
of stem cell guidelines would still afford Maryland the opportunity to 
receive plenty of funding on the state level and from the private sector, 
while remaining atop the ladder in competing for leading scientists in the 
stem cell field.  The economic potential of stem cell research cannot be 
overlooked when national and state debts are increasing and countries 
around the world are joining the fight for top flight stem cell talent.  On the 
heels of the 2009 World Stem Cell Summit held in Baltimore, with states 
debating how to respond to the new federal guidelines, and with the recent 
agreement with California, the time for Maryland to make a statement to the 
stem cell world, and the researchers in it, is now. 
 
